UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 241

Sortiert nach

Role of Oxygen Vacancies in Cr-Doped SrTiO3 for Resistance-Change Memory

Advanced materials (Weinheim), 2007-09, Vol.19 (17), p.2232-2235

2007

Volltextzugriff (PDF)

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

Blood, 2011-07, Vol.118 (2), p.401-408

2011

Volltextzugriff (PDF)

Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population‐based study of 327 patients

British journal of haematology, 2013-01, Vol.160 (2), p.251-254

2013

Volltextzugriff (PDF)

Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients

Haematologica (Roma), 2012-10, Vol.97 (10), p.1570-1573

2012

Volltextzugriff (PDF)

Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group

European journal of haematology, 2019-03, Vol.102 (3), p.235-240

2019

Volltextzugriff (PDF)

Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms

Journal of clinical oncology, 2011-06, Vol.29 (17), p.2410-2415

2011

Volltextzugriff (PDF)

Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real‐world data from the Swedish MPN Registry

European journal of haematology, 2017-06, Vol.98 (6), p.577-583

2017

Volltextzugriff (PDF)

Oxide nanowire networks and their electronic and optoelectronic characteristics

Nanoscale, 2010-01, Vol.2 (1), p.1984-1998

2010

Volltextzugriff (PDF)

Poor Correlation between Pneumococcal IgG and IgM Titers and Opsonophagocytic Activity in Vaccinated Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia

Clinical and vaccine immunology, 2016-04, Vol.23 (4), p.379-385

2016

Volltextzugriff (PDF)

Vaccination against tick-borne encephalitis (TBE) after autologous and allogeneic stem cell transplantation

Vaccine, 2021-02, Vol.39 (7), p.1035-1038

2021

Volltextzugriff (PDF)

A retrospective analysis of the impact of treatments and blood counts on survival and the risk of vascular events during the course of polycythaemia vera

British journal of haematology, 2017-06, Vol.177 (5), p.800-805

2017

Volltextzugriff (PDF)

A phase II study of vorinostat (MK‐0683) in patients with polycythaemia vera and essential thrombocythaemia

British journal of haematology, 2013-08, Vol.162 (4), p.498-508

2013

Volltextzugriff (PDF)

The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients

Blood, 2005-10, Vol.106 (8), p.2862-2864

2005

Volltextzugriff (PDF)

Distinct inflammatory mediator patterns characterize infectious and sterile systemic inflammation in febrile neutropenic hematology patients

PloS one, 2014-03, Vol.9 (3), p.e92319-e92319

2014

Volltextzugriff (PDF)

3D Printed Radar Lenses with Anti-Reflective Structures

Designs, 2019-06, Vol.3 (2), p.28

2019

Volltextzugriff (PDF)

ASXL1 mutations, previous vascular complications and age at diagnosis predict survival in 85 WHO‐defined polycythaemia vera patients

British journal of haematology, 2020-06, Vol.189 (5), p.913-919

2020

Volltextzugriff (PDF)

Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced‐intensity conditioning regimens

British journal of haematology, 2006-11, Vol.135 (3), p.367-373

2006

Volltextzugriff (PDF)

Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia

Haematologica (Roma), 2008-08, Vol.93 (8), p.1260-1261

2008

Volltextzugriff (PDF)

Thromboembolic events, major bleeding and mortality in essential thrombocythaemia and polycythaemia vera—A matched nationwide population‐based study

British journal of haematology, 2024-05, Vol.204 (5), p.1740-1751

2024

Volltextzugriff (PDF)

Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome

Haematologica (Roma), 2016-04, Vol.101 (4), p.e129

2016

Volltextzugriff (PDF)

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study

Blood advances, 2022-01, Vol.6 (2), p.373-375

2022

Volltextzugriff (PDF)

1 – 25 von 241

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(230)
Mit Volltextzugriff
(233)

Publikationsform

Artikel
(236)
Tagungsberichte
(5)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Role of Oxygen Vacancies in Cr-Doped SrTiO3 for Resistance-Change Memory

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population‐based study of 327 patients

Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients

Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group

Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms

Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real‐world data from the Swedish MPN Registry

Oxide nanowire networks and their electronic and optoelectronic characteristics

Poor Correlation between Pneumococcal IgG and IgM Titers and Opsonophagocytic Activity in Vaccinated Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia

Vaccination against tick-borne encephalitis (TBE) after autologous and allogeneic stem cell transplantation

A retrospective analysis of the impact of treatments and blood counts on survival and the risk of vascular events during the course of polycythaemia vera

A phase II study of vorinostat (MK‐0683) in patients with polycythaemia vera and essential thrombocythaemia

The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis

Distinct inflammatory mediator patterns characterize infectious and sterile systemic inflammation in febrile neutropenic hematology patients

3D Printed Radar Lenses with Anti-Reflective Structures

ASXL1 mutations, previous vascular complications and age at diagnosis predict survival in 85 WHO‐defined polycythaemia vera patients

Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced‐intensity conditioning regimens

Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat

Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia

Thromboembolic events, major bleeding and mortality in essential thrombocythaemia and polycythaemia vera—A matched nationwide population‐based study

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients

Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study

Suchergebnisse filtern